Letter to the Editor
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Feb 14, 2022; 28(6): 689-692
Published online Feb 14, 2022. doi: 10.3748/wjg.v28.i6.689
Comments on validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease
Jian-Guo Hong, Lun-Jie Yan, Xian Li, Sheng-Yu Yao, Peng Su, Hai-Chao Li, Zi-Niu Ding, Dong-Xu Wang, Zhao-Ru Dong, Tao Li
Jian-Guo Hong, Lun-Jie Yan, Xian Li, Sheng-Yu Yao, Hai-Chao Li, Zi-Niu Ding, Dong-Xu Wang, Zhao-Ru Dong, Tao Li, Department of General Surgery, Qilu Hospital of Shandong University, Jinan 250012, Shandong Province, China
Peng Su, Department of Pathology, Qilu Hospital of Shandong University, Jinan 250012, Shandong Province, China
Author contributions: Li X and Yao SY designed and performed the research; Yan LJ, Li HC and Ding ZN analyzed the data; Li T and Hong JG wrote the letter; Yan LJ, Su P, Wang DX and Dong ZR revised the letter; Hong JG, Yan LJ, Li X, Yao SY, and Su P contributed equally to this article.
Conflict-of-interest statement: The authors have no conflicts of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tao Li, MD, Chief Doctor, Department of General Surgery, Qilu Hospital of Shandong University, No. 107 West Wenhua Road, Jinan 250012, Shandong Province, China. litao7709@126.com
Received: October 5, 2021
Peer-review started: October 5, 2021
First decision: November 15, 2021
Revised: December 5, 2021
Accepted: January 17, 2022
Article in press: January 17, 2022
Published online: February 14, 2022
Processing time: 126 Days and 14.9 Hours
Core Tip

Core Tip: The concept of metabolic associated fatty liver disease (MAFLD) was proposed in 2020. Unlike the concept of nonalcoholic fatty liver disease, the exclusion of chronic liver disease was not required in the establishment of diagnosis of MAFLD, but the presence of metabolic associated disease or dysfunction is required. The clinical prediction values and the optimal cutoff values of non-invasive fibrosis scores remain unknown. We read the recent article entitled “Validation of Conventional Non-invasive Fibrosis Scoring Systems in Patients with Metabolic Associated Fatty Liver Disease” with great interest. We would like to share our opinions and criticisms about this valuable work.